Loading...

Home
ETF
ARCT

ARCT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ARCT News

Arcturus Therapeutics Q4 2025 Earnings Call Insights

6d agoseekingalpha

Arcturus Therapeutics Reports Disappointing Earnings

6d agoseekingalpha

Arcturus Therapeutics Set to Announce Q4 Earnings on March 3rd

Mar 02 2026seekingalpha

Arcturus to Present mRNA Technologies at J.P. Morgan Healthcare Conference

Jan 08 2026Businesswire

Arcturus Announces Launch of 12-Week Cystic Fibrosis Study in 2026, Facing Cost Management and KOSTAIVE BLA Delays

Nov 10 2025SeekingAlpha

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

Nov 10 2025PRnewswire

Cathie Wood Reduces Holdings in AMD and Other U.S. Tech Stocks, Increases Investment in Baidu and Biotech Sectors

Oct 25 2025TipRanks

Molina Healthcare Analyst Adopts Bearish Stance; Check Out the Top 5 Downgrades for Friday

Oct 24 2025Benzinga

Citi Downgrades Arcturus to Neutral Following mRNA Candidate Data Release

Oct 24 2025SeekingAlpha

Cathie Wood Makes Major Investments in Alibaba, Baidu, and Arcturus While Reducing Holdings in AMD, SoFi, and Shopify

Oct 24 2025TipRanks

Investor Notice: Pomerantz Law Firm Probes Allegations for Arcturus Therapeutics Holdings Inc. Investors - ARCT

Oct 24 2025Globenewswire

Cathie Wood Invests Heavily in This Undervalued Biotech Stock

Oct 23 2025TipRanks

Citigroup Lowers Arcturus Therapeutics Rating to Neutral and Reduces Price Target to $12

Oct 23 2025Benzinga

Analyst Observes Mixed Results as Arcturus' Investigational Inhaled Therapy Shows No Significant Lung Function Improvement

Oct 22 2025Benzinga

BTIG Reaffirms Buy Rating for Arcturus Therapeutics, Reduces Price Target to $23

Oct 22 2025Benzinga

Guggenheim Lowers Arcturus Therapeutics Rating to Neutral

Oct 22 2025Benzinga